NT$ 54
Key Takeaways
Risk factor
Limited trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Solid dividends
Data is available to registered users only
Data is available to registered users only
About
Established in 2001 and headquartered in Kaohsiung, Taiwan, SciVision Biotech Inc. specializes in the development and marketing of products derived from hyaluronic acid. The company's diverse portfolio, available across Taiwan, includes joint lubrication supplements, cosmetic facial fillers, dissolvable barriers designed to prevent surgical adhesions, and treatments administered directly into the bladder.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Data is available to registered users only